Minerva Neurosciences jumps after hedge fund reveals stake

Minerva Neurosciences

24/08/2022 11:34

** Drug developer Minerva Neurosciences' shares  NERV.O 
rise 21.7% to $5.49 - among the biggest gainers across U.S.
stock exchanges premarket
    ** Billionaire investor Steve Cohen's Point72 asset
management reports an 8.8% passive stake in company, according
to a regulatory filing  urn:newsml:reuters.com:*:nEOLq8spd
    ** NERV shares are up 45% since Monday, after U.S. FDA
approved its experimental therapy, roluperidone, to treat
negative symptoms in patients with schizophrenia  urn:newsml:reuters.com:*:nL4N2ZY2PD
    ** Up to Tuesday's close, stock had lost ~30% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))